Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KIN131A
- Development stage
- Preclinical
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
KIN131A is an investigational small-molecule agonist of the cytosolic pattern recognition receptor retinoic acid-inducible gene I (RIG-I), being developed as an intratumoral immuno-oncology agent to stimulate innate antiviral-like signaling and promote antitumor immunity.[1][3] Preclinical data presented by Kineta Immuno-oncology show that KIN131A activates RIG-I signaling, leading to interferon-driven immune responses, inhibition of tumor growth, enhanced survival, and in some models complete tumor regression, indicating potential utility as a local immunotherapy for solid tumors.[1][3]
02
Targets
DDX58 (Retinoic acid-inducible gene I protein)
Beyond the preview
Go deeper on KIN131A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KIN131A.